A share price of Vir Biotechnology Inc [VIR] is currently trading at $5.86, up 1.03%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VIR shares have gain 4.83% over the last week, with a monthly amount glided 17.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on September 03, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $12. Previously, BofA Securities upgraded its rating to Buy on August 27, 2025, and kept the price target unchanged to $14. On January 29, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $9 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $14 on September 08, 2023. JP Morgan upgraded its rating to a Overweight and reduced its price target to $34 on March 06, 2023. Goldman upgraded its rating to Buy for this stock on February 21, 2023, and upped its price target to $53. In a note dated January 27, 2023, Morgan Stanley upgraded an Equal-Weight rating on this stock and boosted its target price from $18 to $30.
Vir Biotechnology Inc experienced fluctuations in its stock price throughout the past year between $4.16 and $14.45. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $5.86 at the most recent close of the market. An investor can expect a potential return of 104.78% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Trailing Twelve Months sales for Vir Biotechnology Inc [NASDAQ:VIR] were 19.00M which represents -60.52% decline. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -35.62%, Pretax Profit Margin comes in at -33.0%, and Net Profit Margin reading is -33.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.5 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vir Biotechnology Inc [NASDAQ:VIR] is 7.01. As well, the Quick Ratio is 7.01, while the Cash Ratio is 2.85. Considering the valuation of this stock, the price to sales ratio is 42.85, the price to book ratio is 0.86.
Transactions by insiders
Recent insider trading involved SVF Endurance (Cayman) Ltd, 10% Owner, that happened on Oct 08 ’25 when 0.47 million shares were sold. 10% Owner, SVF Endurance (Cayman) Ltd completed a deal on Oct 07 ’25 to sell 72133.0 shares. Meanwhile, 10% Owner SVF Endurance (Cayman) Ltd sold 0.45 million shares on Oct 03 ’25.
